Allogeneic hematopoietic cell transplantation cures hematologic diseases but is limited by acute graft‑versus‑host disease. How human T cell clones drive epithelial injury remains poorly mapped. We studied 31 transplant recipients, integrating longitudinal T cell antigen receptor (TCR) profiling with single-cell RNA se...
Ling-Ting Shi, Ajna Uzuni, X. Wang et al.· Nature Immunology· 0 citations
Among adult ACCESS recipients treated on a uniform young-donor PBSC/PTCy platform, short-term outcomes with predominantly 6/8 MMUD transplantation were encouraging and should not be interpreted as establishing equivalence with 7/8 MMUD transplantation.
A. J. Jimenez Jimenez, Joseph Stanek, Brent Logan et al.· Blood Advances· 0 citations
MMUD with PTCy-based GVHD prophylaxis and RIC/NMA conditioning was safe and effective to facilitate HCT and outcomes were similar in the expansion cohort that enrolled from a greater number of centers.
Brian C. Shaffer, M. A. Al Malki, Antonio M. Jimenez et al.· American journal of hematolo...· 0 citations
A multicenter, retrospective study of patients with LBCL assessed in real time with a commercially available, immunoglobulin rearrangement-targeted ctDNA-MRD assay (clonoSEQM), finding post-treatment MRD after immunochemotherapy or chimeric antigen receptor T-cell (CAR-T) therapy was 15% versus 85% for detectable versu...
Patrick Gould, D. Coskey, Xin Ma et al.· Haematologica· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.